Tsurui T, Hamada K, Mura E, Suzuki R, Iriguchi N, Ishiguro T
Front Oncol. 2025; 15:1499650.
PMID: 39980541
PMC: 11839410.
DOI: 10.3389/fonc.2025.1499650.
Zha B, Ma Y, Zha B, Guo X
Eur Radiol. 2025; .
PMID: 39884988
DOI: 10.1007/s00330-025-11394-7.
Aru N, Yang C, Chen Y, Liu J
BMC Cancer. 2025; 25(1):43.
PMID: 39780132
PMC: 11716173.
DOI: 10.1186/s12885-025-13430-7.
Zhong W, Huang W, Deng H, Qiu S, Yang Q, Jia H
BMC Complement Med Ther. 2025; 25(1):1.
PMID: 39754159
PMC: 11697957.
DOI: 10.1186/s12906-024-04732-7.
Procopio S, Esser K
J Mol Cell Cardiol. 2024; 198:36-44.
PMID: 39615287
PMC: 11780665.
DOI: 10.1016/j.yjmcc.2024.11.011.
Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation.
Ucgul E, Guven D, Ucgul A, Ozbay Y, Onur M, Akin S
Cancer Control. 2024; 31:10732748241302248.
PMID: 39547932
PMC: 11569492.
DOI: 10.1177/10732748241302248.
Sarcopenia predicts immune-related adverse events due to anti-PD-1/PD-L1 therapy in patients with advanced lung cancer.
Xue D, Li N, Yang J, Men K, Li L, Jiang H
Front Oncol. 2024; 14:1450020.
PMID: 39376979
PMC: 11456396.
DOI: 10.3389/fonc.2024.1450020.
Molecular composition of skeletal muscle in infants and adults: a comparative proteomic and transcriptomic study.
Schaiter A, Hentschel A, Kleefeld F, Schuld J, Umathum V, Procida-Kowalski T
Sci Rep. 2024; 14(1):22965.
PMID: 39362957
PMC: 11450201.
DOI: 10.1038/s41598-024-74913-4.
The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma.
Praktiknjo M, Pena Solano A, Sadeghlar F, Welchowski T, Schmid M, Mohring C
Sci Rep. 2024; 14(1):22146.
PMID: 39333610
PMC: 11437060.
DOI: 10.1038/s41598-024-66766-8.
The impact of ageing mechanisms on musculoskeletal system diseases in the elderly.
Cai Y, Han Z, Cheng H, Li H, Wang K, Chen J
Front Immunol. 2024; 15:1405621.
PMID: 38774874
PMC: 11106385.
DOI: 10.3389/fimmu.2024.1405621.
Dexamethasone-induced muscle atrophy and bone loss in six genetically diverse collaborative cross founder strains demonstrates phenotypic variability by Rg3 treatment.
Nguyen B, Hong S, Choi S, Lee C, Yoo G, Kim M
J Ginseng Res. 2024; 48(3):310-322.
PMID: 38707648
PMC: 11069000.
DOI: 10.1016/j.jgr.2023.12.004.
Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
Liu M, Jin Q, Wang H, Li Y
Front Immunol. 2024; 15:1396927.
PMID: 38690276
PMC: 11058658.
DOI: 10.3389/fimmu.2024.1396927.
Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.
Nunes A, Ramirez M, Garcia-Collazo E, Jones T, Jones P
Hum Mol Genet. 2024; 33(10):872-883.
PMID: 38340007
PMC: 11070135.
DOI: 10.1093/hmg/ddae019.
Body composition is associated with postoperative complications in perihilar cholangiocarcinoma.
Wang G, Mantas A, Heij L, Al-Masri T, Liu D, Heise D
Cancer Med. 2024; 13(1):e6878.
PMID: 38164056
PMC: 10807576.
DOI: 10.1002/cam4.6878.
Beyond Inflammaging: The Impact of Immune System Aging on Age-Related Muscle Decline, Results From the InCHIANTI Study.
Pellegrino R, Paganelli R, Di Iorio A, Bandinelli S, Moretti A, Iolascon G
J Gerontol A Biol Sci Med Sci. 2023; 79(2).
PMID: 37795971
PMC: 10799757.
DOI: 10.1093/gerona/glad238.
Body composition as a predictor of oncological outcome in patients with non-muscle-invasive bladder cancer receiving intravesical instillation after transurethral resection of bladder tumor.
Huang L, Lin Y, Chuang H, Chuang C, Pang S, Wu C
Front Oncol. 2023; 13:1180888.
PMID: 37637042
PMC: 10448957.
DOI: 10.3389/fonc.2023.1180888.
Low Muscle and High Fat Percentages Are Associated with Low Natural Killer Cell Activity: A Cross-Sectional Study.
Cho A, Suh E, Oh H, Cho B, Gil M, Lee Y
Int J Mol Sci. 2023; 24(15).
PMID: 37569879
PMC: 10419953.
DOI: 10.3390/ijms241512505.
Inflammation o'clock: interactions of circadian rhythms with inflammation-induced skeletal muscle atrophy.
Morena da Silva F, Esser K, Murach K, Greene N
J Physiol. 2023; 602(23):6587-6607.
PMID: 37563881
PMC: 10858298.
DOI: 10.1113/JP284808.
Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia.
Tenuta M, Pandozzi C, Sciarra F, Campolo F, Gelibter A, Sirgiovanni G
Cancers (Basel). 2023; 15(14).
PMID: 37509255
PMC: 10377538.
DOI: 10.3390/cancers15143592.
Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis.
Surov A, Strobel A, Borggrefe J, Wienke A
Eur Radiol. 2023; 33(9):6426-6437.
PMID: 36929392
DOI: 10.1007/s00330-023-09524-0.